With increasing availability of nucleic acid testing (NAT) methods, measuring EBV DNA in blood has proven valuable in diagnosing and monitoring PTLD [16,21,22,37-41], NPC [42,43], IM [13,44], EBV infection in HIV-infected individuals [8,13,45], BL [13] and chronic active EBV infection [18,46]. This evidence concerns the gene BRD2 and post-transplant lymphoproliferative disease.